Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy

Journal of Hypertension

Volumn 23, Issue 3, 2005, Pages 633-640

  Müller Brunotte, Richard ^a   Edner, Magnus ^a   Malmqvist, Karin ^a   Kahan, Thomas ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Angiotensin II; Diastolic function; Echocardiography; Hypertension; Left ventricular hypertrophy

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATENOLOL; HYDROCHLOROTHIAZIDE; IRBESARTAN; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD FLOW VELOCITY; BLOOD PRESSURE; BODY MASS; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLE; DISEASE DURATION; DOPPLER ECHOCARDIOGRAPHY; DOUBLE BLIND PROCEDURE; FEMALE; HEART ATRIOVENTRICULAR VALVE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPEN STUDY; PRIORITY JOURNAL; PULMONARY VEIN; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STATISTICAL ANALYSIS;

EID: 18844424323     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000160222.17092.b8     Document Type: Article

References (33)

1. Safar ME, Lehner JP, Vincent MI, Plainfosse MT, Simon AC. Echocardiographic dimensions in borderline and sustained hypertension. Am J Cardiol 1979; 44:930-935.
2. Dunn FG, McLenachan J, Isles CG, Brown I, Dargie HJ, Lever AF, et al. Left ventricular hypertrophy and mortality in hypertension: an analysis of data from the Glasgow Blood Pressure Clinic. J Hypertens 1990; 8:775-782.
3. Hammond IW, Devereux RB, Alderman MH, Lutas EM, Spitzer MC, Crowley JS, et al. The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol 1986; 7:639-650.
4. Savage DD, Drayer JI, Henry WL, Mathews EC Jr, Ware JH, Gardin JM, et al. Echocardiographic assessment of cardiac anatomy and function in hypertensive subjects. Circulation 1979; 59:623-632.
5. Schillaci G, Pasqualini L, Verdecchia P, Vaudo G, Marchesi S, Porcellati C, et al. Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol 2002; 39:2005-2011.
6. Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol 2001; 37:1042-1048.
7. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996; 275:1557-1562.
8. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83:1849-1865.
9. Malmqvist K, Kahan T, Edner M, Held C, Hägg A, Lind L, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19:1167-1176.
10. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988; 108:7-13.
11. Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 1995; 25:879-884.
12. Höglund C, Alam M, Thorstrand C. Atrioventricular valve plane displacement in healthy persons. An echocardiographic study. Acta Med Scand 1988; 224:557-562.
13. Zaky A, Grabhorn L, Feigenbaum H. Movement of the mitral ring: a study in ultrasoundcardiography. Cardiovasc Res 1967; 1:121-131.
14. Alam M, Höglund C. Assessment by echocardiogram of left ventricular diastolic function in healthy subjects using the atrioventricular plane displacement. Am J Cardiol 1992; 69:565-568.
15. Müller-Brunotte R, Edner M, Malmqvist K, Edner M. Blood pressure and left ventricular geometric pattern determine diastolic function in hypertensive myocardial hypertrophy. J Hum Hypertens 2003; 17:841-849.
16. Isobe N, Taniguchi K, Oshima S, Ono Z, Adachi H, Toyama T, et al. Candesartan cilexetil improves left ventricular function, left ventricular hypertrophy, and endothelial function in patients with hypertensive heart disease. Circ J 2002; 66:993-999.
17. Thürmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98:2037-2042.
18. Cuspidi C, Muiesan ML, Valagussa L, Salvetti M, Di Biagio C, Agabiti-Rosei E, et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002; 20:2293-2300.
19. Dahlöf B, Zanchetti A, Díez J, Nicholls MG, Yu CM, Barrios V, et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002; 20:1855-1864.
20. Mazzolai L, Pedrazzini T, Nicoud F, Gabbiani G, Brunner HR, Nussberger J. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension 2000; 35:985-991.
21. Schmieder RE, Messerli FH, Garavaglia GE, Nunez B, MacPhee AA, Re RN. Does the renin-angiotensin-aldosterone system modify cardiac structure and function in essential hypertension? Am J Med 1988; 84:136-139.
22. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102:1388-1393.
23. Malmqvist K, Öhman KP, Nyström F, Lind L, Kahan T. Long term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension. J Cardiovasc Pharmacol 2003; 42:719-726.
24. Agabiti-Rosei E, Muiesan ML. Left ventricular diastolic function in essential hypertension. Contrib Nephrol 1994; 106:174-178.
25. Varo N, Etayo JC, Zalba G, Beaumont J, Iraburu MJ, Montiel C, et al. Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens 1999; 17:107-114.
26. Ohno M, Cheng CP, Little WC. Mechanism of altered patterns of left ventricular filling during the development of congestive heart failure. Circulation 1994; 89:2241-2250.
27. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114:345-352.
28. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97:48-54.
29. Oh JK, Appleton CP, Hatle LK, Nishimura RA, Seward JB, Tajik AJ. The noninvasive assessment of left ventricular diastolic function with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 1997; 10:246-270.
30. Wandt B, Bojo L, Tolagen K, Wranne B. Echocardiographic assessment of ejection fraction in left ventricular hypertrophy. Heart 1999; 82:192-198.
31. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362:777-781.
32. Vachiery JL. ACE inhibitors and/or sartans in heart failure: is there a difference? Rev Med Brux 2003; 24:A249-A252.
33. Bergström A, Andersson B, Edner M, Nylander E, Persson H, Dahlström U. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 2004; 6:453-461.